Year: 2023
Type: article
Abstract: Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid-β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association. After numerous unsuccessful endeavors to create a disease-modifying therapy for Alzheimer's disease, substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid-β is finally emerging. The latest trials not only achieved their primary objective of slowing the progression of the disease over several months but also demonstrated positive secondary clinical outcomes and a decrease in amyloid-β levels as observed through positron emission tomography scans. Taken as a whole, these findings mark a significant breakthrough by substantiating that reducing amyloid-β yields tangible clinical benefits, beyond mere changes in biomarkers. Concurrently, the regular utilization of the new generation of drugs will determine whether statistical efficacy translates into clinically meaningful improvements. This may well signify the dawning of a new era in the development of drugs for Alzheimer's disease.
Source: European Journal of Neurology
DOI: 10.1111/ene.16049
Institutions: German Center for Neurodegenerative Diseases, LMU Klinikum, Munich Cluster for Systems Neurology, Imperial College London, Ludwig-Maximilians-Universität München, University of Sheffield, University of Antwerp, European Psychiatric Association, University of Bern, University Hospital of Bern, Max Planck Institute of Psychiatry, European Academy of Neurology
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
OpenAlex ID: W4386623568